IVB107

IVB107 (also known as PUNC-H-E101) is an investigational adeno-associated virus (AAV) gene therapy developed by InnoVec Biotherapeutics for the treatment of rare and common ocular diseases. The therapy utilizes a proprietary, modified AAV capsid designated as VF18, which is engineered to optimize retinal transduction following intravitreal administration. By delivering therapeutic transgenes directly to the eye via a less invasive intravitreal injection, IVB107 aims to overcome the limitations of traditional AAV vectors that often require subretinal delivery. The program is currently being evaluated in investigator-initiated trials (IIT) to establish safety and proof-of-concept for its novel capsid technology and therapeutic approach.